Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Rapid Novor

Rapid Novor
2015 FOUNDED
PRIVATE STATUS
Accelerator/Inc LATEST DEAL TYPE
2 INVESTORS
Description

Provider of antibody protein sequencing technology intended to develop antibody proteins for pharmaceutical companies. The company's services produce new antibody directly from sample with sequence accuracy and have the same binding affinity and also mass uses spectrometry to restore hybridoma cell line, confirm antibody product, examine post-translational modifications and glycosylations and accelerate biosimilar development, enabling medical researchers to develop and advance life science for better human health with next generation protein sequencing.

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Pharmaceuticals
Other Healthcare Services
Other Software
Primary Office
  • 44 Gaukel Street
  • 2nd Floor
  • Kitchener, Ontario N2G 4P3
  • Canada

+1 (855) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Rapid Novor’s full profile, request a free trial.

Rapid Novor Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Accelerator/Incubator 12-Feb-2018 Completed Generating Revenue
1. Accelerator/Incubator 20-Jul-2017 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Rapid Novor Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
JLABS Accelerator/Incubator Minority 000 0000 000000 0
The Accelerator Centre Accelerator/Incubator Minority 000 0000 000000 0

Rapid Novor Executive Team (3)

Name Title Board
Seat
Contact
Info
Mingjie Xie Co-Founder & Chief Executive Officer
Bin Ma Ph.D Co-Founder & President
Qixin Liu Co-Founder & Chief Technology Officer